

Modeling and Simulation

With one of the largest and most experienced in-house teams of modelers, Evidera has designed, developed, and implemented hundreds of health economic and other models in all major therapeutic indications and for all major markets. Although the specific modeling method (e.g., decision tree, state-transition, discrete event simulation, survival partition, discretely integrated condition event) will vary depending on the research question and intended use of the model, all Evidera models are rigorously constructed, verified, and validated in accordance with the most recent modeling guidelines.

Our models have been used by biopharmaceutical and medical device manufacturers to:

- Demonstrate clinical and economic value (e.g., cost-effectiveness)
- Estimate direct and indirect economic burden, as well as budget impact
- Forecast the long-term effects of a therapy when only short-term data are available
- Inform clinical trial design and simulate expected outcomes
- Evaluate pricing scenarios and inform strategic planning and product development
- Support submissions to regulatory agencies and health authorities

Offerings include

Early Modeling

Inform go/no-go decision making and gap analysis

Economic Analysis

Assess interventions by estimating their health outcomes and cost consequences

Budget Impact Analysis

Quantify the financial consequence to payers of adopting an intervention

Epidemiologic Estimates

Forecast the size and makeup of target populations

Local Model Adaptations

Adjust models to specific countries to facilitate market access

STC and MAIC

Simulated Treatment Comparisons (STC) and Matching-Adjusted Indirect Comparisons (MAIC)

Disease Simulation

Understand the natural history of disease, its impact on patients and costs, and how interventions can modify these outcomes

Multi-Criteria Decision Analysis

(MCDA) Synthesize multiple sources of data to support investment decisions, benefit-risk assessments, and payer communications

Alzheimer's Disease ACE Simulator

Support commercial strategy development, inform clinical trial designs, and meet HTA¹ agency requirements for formal submission

Clinical Trial Simulation

Assess the impact of trial design features on the likely outcomes and help identify target populations and estimate sample sizes


Submissions Support

Support submissions to regulatory agencies and health authorities, including NICE, CADTH, and PBAC, among others¹

Crossover Adjustment

Gain valuable information through rank preserving structural failure time (RPSFT) models, inverse probability of censoring weighted (IPCW) analyses, and simulation-based adjustment

Global experience in health economic modeling and simulation



Our Team & EXPERIENCE

— 75+ —

Modelers in Europe, North America, and Asia

— 80+ —

Submissions to payer / health authorities supported

— 600+ —

Engagements to develop or adapt models

— 400+ —

Peer-reviewed publications

Why EVIDERA?

— Innovative —

Advancing current methods and developing new solutions, e.g., Alzheimer's disease ACE simulator, MCDA, clinical trial simulation, and advanced solutions in oncology

— Thought Leaders —

Numerous industry leadership roles, e.g., ISPOR-SMDM Task Force, ISPOR MCDA Task Force, and ISPOR Oncology Special Interest Group²

— Influence —

Developed and communicated evidence to influence payer / health authority decisions, e.g., developed economic model to influence fast-tracking of NICE decision³

¹ NICE = National Institute for Health and Care Excellence; CADTH = Canadian Agency for Drugs and Technologies in Health; PBAC = Pharmaceutical Benefits Advisory Committee; HTA = Health Technology Assessment

² www.ispor.org/taskforces/grpmodelingtf.asp, www.ispor.org/taskforces/multi-criteria-decision-analysis-grp.asp, www.ispor.org/sigs/oncology.asp

³ www.nice.org.uk/News/Press-and-Media/nice-recommends-new-treatment-for-people-with-common-heart-condition